Abstract:Osteosarcoma (OS) is an aggressive pediatric solid tumor that is difficult to treat with established therapies. We mined the DepMap data in 13 OS cell line this data to identify enriched dependencies whose knockout (KO) leads to selective anti-viability in OS. We observed that SMARCAL1 as a selective dependency in OS (p<0.0001; effect size = -0.275). We reasoned that SMARCAL1 is important given the genomic instability of OS and SMARCAL1's known role in replication stress. We first validated screen findings by CRISPR KO in OS lines in vitro. This demonstrated selective antiviability effect of SMARCAL1 KO in dependent OS lines. To orthogonally validate SMARCAL1 dependency, we deployed a dTAG system that utilizes a hetero-bifunctional small molecule targeting the tagged protein for degradation by an E3 ubiquitin ligase. We observed significant antiviability of dependent OS after SMARCAL1 degradation. In parallel, in order to ascertain SMARCAL1's relevance as a target in OS in vivo, we performed a pooled barcoded CRISPR screen (n=1,626 guides) against pre-selected OS dependencies in an OS cell line xenograft in NSG mice. After sequencing of tumor gDNA, we identified SMARCAL1 as a top hit, suggesting its importance in OS in vivo. We next investigated biomarkers of SMARCAL1 dependency. A role for SMARCAL1 has been described in alternative lengthening of telomeres (ALT). With this knowledge, we asked whether ALT+ OS lines are enriched for SMARCAL1 dependence. We found a correlation between ALT+ OS and SMARCAL1 dependence in our CRISPR screens. We then asked if this extends to other ALT+ tumors. Neuroblastoma (NB), the most common extracranial pediatric solid tumor, is ALT-enriched. When we looked specifically at NB, we observed that SMARCAL1 was the most enriched dependency in ALT+ NB compared with other NB lines (p<0.0001; effect size = -0.785). When then performed KO of SMARCAL1 in 2 ALT+ ATRX altered NB lines and one ALT+ ATRX wildtype (WT) NB line. We found that SMARCAL1 KO led to antiviability in ATRX altered ALT+ cell lines, while the ALT+, ATRX WT cell line was unaffected. This suggests that dependency on SMARCAL1 is specific to ATRX/DAXX alteration, rather than only ALT. In order to confirm synthetic lethality between ATRX and SMARCAL1, we next utilized a human OS line which has biallelic inactivation of SMARCAL1. We infected this line with our SMARCAL1 dTAG, leading to constitutive overexpression of tagged SMARCAL1, and then performed ATRX CRISPR KO. We observed that SMARCAL1 overexpression rescued the antiviability effect of ATRX KO, and that this could be reversed by degradation of exogenous SMARCAL1, suggesting that ATRX and SMARCAL1 can compensate for one another. Taken together, these findings demonstrate that SMARCAL1 is a selective dependency that is engendered by the loss of WT ATRX/DAXX in OS and NB and that SMARCAL1 is playing a critical role in mediating ALT. Studies are ongoing to determine the mechanism of SMARCAL1's activity and potential for targeting this enzyme for therapeutic benefit. Citation Format: Monika Wierdl, Jerrel L. Catlett, Nicole Ocasio-Martinez, John D. Johnson Jr, Amy Herman, Neekesh V. Dharia, Gabriela Alexe, E. Alejandro Sweet-Cordero, Emily Bernstein, Kimberly Stegmaier, Lillian M. Guenther. SMARCAL1 is a selective dependency and a novel synthetic lethal target in ATRX/DAXX mutant ALT+ osteosarcoma and neuroblastoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr PR004.

TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT

Selective Elimination of Osteosarcoma Cell Lines with Short Telomeres by Ataxia Telangiectasia and Rad3-Related Inhibitors

Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants

Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas

Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells

Phosphorylation of 'SDT-like' motifs in ATRX mediates its interaction with the MRN complex and is important for ALT pathway suppression

UTX Inhibition As Selective Epigenetic Therapy Against TAL1-driven T-cell Acute Lymphoblastic Leukemia

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner

Abstract B14: Establishment and characterization of in vitro models of alternative lengthening of telomeres (ALT) in pediatric high-grade glioma

Topoisomerase IIIα is required for normal proliferation and telomere stability in alternative lengthening of telomeres

Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX

Orphan nuclear receptors promote alternative lengthening of telomeres (ALT) through ALT-associated PML bodies

LAP2α orchestrates alternative lengthening of telomeres suppression through telomeric heterochromatin regulation with HDAC1: unveiling a potential therapeutic target

Abstract A06: A novel cell line model of the alternative lengthening of telomeres (ALT) telomere maintenance mechanism

Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells

Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function

Abstract B023: SMARCAL1 is a novel candidate therapeutic target for ALT-positive osteosarcoma

Abstract 3949: SMARCAL1 is a novel synthetic lethal target in ALT+ osteosarcoma and neuroblastoma

Switch Telomerase to ALT Mechanism by Inducing Telomeric DNA Damages and Dysfunction of ATRX and DAXX.

Abstract PR004: SMARCAL1 is a selective dependency and a novel synthetic lethal target in ATRX/DAXX mutant ALT+ osteosarcoma and neuroblastoma